| Mar'19 | Mar'18 | Mar'17 | ||||
|---|---|---|---|---|---|---|
Operating expenses: | ||||||
Research and development | ||||||
22,173 | 13,516 | 6,936 | ||||
General and administrative | ||||||
8,773 | 5,713 | 2,711 | ||||
Total operating expenses | ||||||
30,946 | 19,229 | 9,647 | ||||
Loss from operations | ||||||
-30,946 | -19,229 | -9,647 | ||||
Other income (expense): | ||||||
Research and development incentives | ||||||
2,528 | 2,267 | 1,442 | ||||
Investment income | ||||||
2,585 | 288 | 25 | ||||
Change in fair value of warrant liability | ||||||
5,452 | 972 | 150 | ||||
Other income (expense) | ||||||
451 | -2,056 | 626 | ||||
Total other income (expense), net | ||||||
112 | -473 | 1,943 | ||||
Net loss | ||||||
-30,834 | -19,702 | -7,704 | ||||
Net loss attributable to common stockholders | ||||||
-30,834 | -19,702 | -7,704 | ||||
Net loss per share attributable to common shareholders, basic and diluted (in dollars per share) | ||||||
-1.33 | -3.96 | -1.55 | ||||
Weighted average common shares outstanding-basic and diluted (in shares) | ||||||
23,198 | 4,978 | 4,973 | ||||